

MIG Fonds' portfolio company BioNTech receives first COVID-19 vaccine approval – private risk capital was crucial

- *First COVID-19 and mRNA vaccine worldwide - BNT162b2 - developed by BioNTech and its partner Pfizer was approved in the UK*
- *MIG is a founding investor and long-term active shareholder of BioNTech*
- *Development of BNT162b2 would not have been possible without risk capital from German private investors*
- *MIG congratulates BioNTech and partner Pfizer, and is proud to be a part of this extraordinary achievement for Global Public Health*
- *BioNTech confirms MIG's cross-sectoral tech focused investment strategy*

München, GERMANY, December 2, 2020 – MIG AG, the manager of MIG Fonds, a founding investor of BioNTech SE, today announces its portfolio company and its U.S. partner Pfizer Inc. have received the first approval of its COVID-19 vaccine BNT162b2, from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA). The emergency approval represents the first authorization of both a COVID-19 and mRNA vaccine ever.

MIG, a German venture capital investment company focusing on life sciences and deep tech companies, congratulates BioNTech and its partners for successfully working together in this critical effort to support the Global Public Health system and billions of people. The development of this vaccine, and many other medicines combating serious diseases, was made possible with generous investments from both public and private institutions. MIG Fonds with its German and Austrian private investors, together with the strong commitment of the Strüngmann family office and other contributors, substantially supported the founding of BioNTech in 2008 and its growth strategy over the years including the Nasdaq IPO.

“The world is a more hopeful place with today's approval of a vaccine to combat the SARS-CoV-2 pandemic. This success is a great example of private and public institutions working together to move the world forward. Here we see the value of the model where private investors and venture capitalists took the risk of investing in innovation at a very early stage of the company over many years, while pharma and public funding stepped in later on. With this approach, we can lay the foundation for future innovations offering more break-through solutions for mankind. At MIG, we are proud of having supported this achievement from the very beginning and feel encouraged to remain committed to investing in young and innovative companies in disruptive technology areas. Innovation needs risk capital,” said Michael Motschmann, General Partner and Board Member of MIG.

“BioNTech is also a great example of how technology and life sciences continue to grow together,” Motschmann continues. “As the company successfully applies several deep technologies like machine learning, data analytics and automation & robotics for its biopharmaceutical developments, BioNTech represents an ideal investment case for MIG's cross-sectoral, technology- focused and long-term investment strategy.”

About MIG AG

MIG Verwaltungs AG (MIG AG) is one of the leading German VC investors. MIG AG, through its MIG Fonds, invests in early-stage deep tech and life science technologies in German-speaking Europe and beyond. The company has so far invested over € 580 m in more than 40 companies. Its portfolio companies are developing innovations in the fields of biopharmaceuticals, artificial intelligence/machine learning, quantum tech, Digitization/IOT, precision medicine and digital health. Currently, the MIG investment portfolio includes 27 companies.

The MIG investment team is a committed group of engineers, biologists, scientists and investors who understand the importance of an analytical and creative approach to the opportunities and challenges faced when trying to build a successful business. Their reputation and track record provides an excellent access to the people, firms and institutions that matter for its portfolio companies' growth.

Further information at www.mig.ag, www.mig-fonds.de

Contact:

MIG AG

Dr. Matthias Kromayer

General Partner und Board Member

+49-89-94382680

mbe@mig.ag

Media requests:

MC Services

Julia Hofmann (+49-89-210228-0)

Catherine Featherston, (+49 170 1137 305)

Shaun Brown (+44-7867-515918)

migag@mc-services.eu